NeuroSense Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.9%.

Top 18 shareholders own 26.59% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
15.8%	Alon Ben-Noon	3,081,600	US$2.8m	0%	no data
5.31%	Ariel Gordon	1,034,607	US$931.1k	0%	no data
2.36%	Or Eisenberg	460,008	US$414.0k	0%	no data
0.63%	Ferenc Tracik	122,951	US$110.7k	0%	no data
0.41%	Cantor Fitzgerald Asset Management	79,492	US$71.5k	0%	no data
0.34%	Niva Russek-Blum	65,428	US$58.9k	0%	no data
0.33%	Mark Leuchtenberger	64,000	US$57.6k	0%	no data
0.24%	XTX Holdings Limited, Asset Management Arm	45,996	US$41.4k	40.9%	no data
0.21%	Meitav Investment House Ltd	40,000	US$36.0k	0%	no data
0.18%	Citadel Advisors LLC	34,280	US$30.9k	0%	no data
0.15%	Revital Mandil-Levin	28,526	US$25.7k	0%	no data
0.12%	Cary Claiborne	24,000	US$21.6k	0%	no data
0.12%	Christine Pellizzari	24,000	US$21.6k	0%	no data
0.12%	Caren Deardorf	24,000	US$21.6k	0%	no data
0.11%	Hagit Binder	22,000	US$19.8k	0%	no data
0.065%	Commonwealth Equity Services, LLC	12,625	US$11.4k	0%	no data
0.061%	Geode Capital Management, LLC	11,963	US$10.8k	0%	no data
0.0051%	Carson Wealth Management Group	1,000	US$900.7	0%	no data